Gain Therapeutics Reports Positive Phase 1 Clinical Trial Results
Gain Therapeutics, Inc. (Nasdaq: GANX) has shared encouraging findings from its Phase 1 clinical trial of GT-02287, a new therapy aimed at treating Parkinson’s disease. The results highlight key aspects such as safety, tolerability, pharmacokinetics, and target engagement. The trial included 72 healthy volunteers, consisting of both males and females, all under the age of 64.
Safety and Tolerability of GT-02287
The Phase 1 trial showed that GT-02287 was well tolerated throughout the study, with no significant discontinuations or serious adverse events reported. Importantly, the data indicated that both single and multiple doses of GT-02287 were safe and well tolerated, even at the highest planned dose levels. Notably, around 15% of the participants were over the age of 50, reflecting a diverse age range in the study.
Cerebrospinal Fluid Engagement
Crucially, the study demonstrated that GT-02287 effectively penetrated the cerebrospinal fluid (CSF), which is vital for addressing central nervous system (CNS) disorders. This penetration was accompanied by evidence of target engagement in peripheral areas. The findings bolster the potential of GT-02287 as a leading therapeutic option for Parkinson’s disease patients, regardless of whether they have the GBA1 mutation.
Future Plans for Gain Therapeutics
Gain Therapeutics is eager to push its research forward, planning to launch a Phase 1b trial targeting individuals with Parkinson’s disease by the end of 2024. The main objective of this upcoming trial is to further assess the safety and tolerability of GT-02287 in this specific patient population. Additionally, the trial aims to gather evidence regarding its mechanism of action through relevant biomarkers, with interim results anticipated by mid-2025.
Expert Insights on GT-02287
Dr. Jonas Hannestad, Chief Medical Officer of Gain, expressed optimism about the data collected thus far, emphasizing the strong safety profile and the expected progression into further clinical trials. He highlighted the importance of demonstrating tolerability in patients with Parkinson’s disease and noted that the research team is eagerly awaiting the upcoming results.
About GT-02287 and Its Development
GT-02287 is Gain Therapeutics’ leading drug candidate, specifically designed to target Parkinson’s disease linked to the GBA1 gene mutation. This orally administered therapy functions as an allosteric protein modulator, aimed at restoring the activity of the glucocerebrosidase (GCase) enzyme. Deficiencies in this enzyme, often caused by genetic mutations and age-related stressors, can contribute to the symptoms of Parkinson’s disease.
Preclinical Achievements
In preclinical models, GT-02287 showed the ability to restore GCase functionality while reducing aggregated ?-synuclein, alleviating neuroinflammation, and preventing neuronal death. Additionally, improvements in dopamine levels and both motor and cognitive performance were observed. Significant reductions in plasma neurofilament light chain levels were also noted, establishing GT-02287 as a promising candidate for slowing neurodegenerative processes.
Supporting Research and Funding
The development of GT-02287 has received financial support from organizations such as The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation. This backing also includes participation in the Eurostars-2 program, along with co-funding from the European Union’s Horizon 2020 initiative and Innosuisse – Swiss Innovation Agency.
Innovative Drug Discovery at Gain Therapeutics
Gain Therapeutics utilizes its proprietary Magellan™ drug discovery platform, which employs AI-supported structural biology and advanced virtual screening techniques to identify new allosteric binding sites on proteins involved in various diseases. This innovative platform facilitates the discovery of promising small molecule candidates that could potentially transform treatment protocols for challenging conditions, including neurodegenerative disorders and rare genetic diseases.
Frequently Asked Questions
What is the primary focus of Gain Therapeutics?
Gain Therapeutics is dedicated to developing allosteric therapies for neurodegenerative diseases, with their lead drug candidate GT-02287 specifically targeting Parkinson’s disease.
What are the key findings from the Phase 1 trial?
The trial revealed that GT-02287 is safe and well-tolerated in healthy subjects, with significant CNS penetration and target engagement observed.
When are the next trials for GT-02287 expected to start?
A Phase 1b trial involving Parkinson’s disease patients is anticipated to begin by the end of 2024.
What achievements has GT-02287 made in preclinical studies?
Preclinical studies have shown that GT-02287 restores enzyme function, decreases neuroinflammation, and enhances cognitive and motor functions.
What is the significance of the funding received by Gain Therapeutics?
Funding from prominent organizations supports the development of GT-02287 and enhances research initiatives aimed at discovering effective treatments for Parkinson’s disease.
